Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes
eJHaem · 2026-06 · 7 (3)
DOI: 10.1002/jha2.70302 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 06.05.2026. Verfasst von Bo-Yu Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology Department of Internal Medicine National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tai…. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Peripheral T‐cell lymphomas (PTCLs) are heterogeneous neoplasms with poor prognosis and marked geographic variation. Data from Taiwan remain limited. We conducted a 15‐year retrospective cohort study of 249 patients diagnosed with PTCL at two major centers in southern Taiwan between 2010 and 2024 to characterize regional epidemiology, real‐world treatment patterns, and survival outcomes. The cohort demonstrated subtype distribution typical of East Asia, with nodal T follicular helper cell lymphoma, angioimmunoblastic type (22%), extranodal NK/T‐cell lymphoma (21%), and PTCL‐NOS (15%) predominating. Most patients presented with high‐risk features: 71% Stage III–IV disease, 47% bone marrow involvement, and 64% elevated LDH. Median overall survival was 17.6 months, and event‐free survival was 6.4 months. Multivariable analysis identified ECOG performance status ≥ 2, elevated LDH, > 1 extranodal site, and age ≥ 60 years as four independent adverse prognostic factors. Frontline hematopoietic stem cell transplantation (HSCT) showed no significant improvement in outcomes; however, salvage chemotherapy followed by HSCT provided prolonged survival after relapse, with median survival after relapse not reached, compared with 6.1 months with salvage chemotherapy alone. These findings underscore PTCL's persistently poor outcomes and the essential role of salvage HSCT in durable survival. Addressing biological complexity and improving therapeutic strategies remain critical for advancing care. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology Department of Internal Medicine National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan.
- Division of Hematology-Oncology Department of Internal Medicine Chi Mei Medical Center Tainan Taiwan.
- Department of Pathology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan.
- Center for Cancer Research Kaohsiung Medical University Kaohsiung Taiwan.
- Institute of Clinical Medicine College of Medicine National Cheng Kung University Tainan Taiwan.
ORCID-Profile: Bo-Yu Huang, Li-Chang Chang, Ya-Ting Hsu
Zitieren
APA
Huang, B. Y., Chang, L. C., Hsiao, S. Y., Chen, Y. P., Li, S. S., Fu, P. A., Chang, C., Chang, K. C., Chen, T. Y., & Hsu, Y. T. (2026). Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes. eJHaem, 7(3). https://doi.org/10.1002/jha2.70302
Vancouver
Huang BY, Chang LC, Hsiao SY, Chen YP, Li SS, Fu PA, et al. Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes. eJHaem. 2026;7(3). doi:10.1002/jha2.70302
BibTeX
@article{Huang2026,
author = {Huang, Bo-Yu and Chang, Li-Chang and Hsiao, Sheng-Yen and Chen, Ya-Ping and Li, Sin-Syue and Fu, Pei-An and Chang, Chen and Chang, Kung-Chao and Chen, Tsai-Yun and Hsu, Ya-Ting},
title = {Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {3},
doi = {10.1002/jha2.70302}
}
EUVIMED